Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.7 |
mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.024 | 0.7 |
mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.7 |
mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.027 | 0.7 |
mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.7 |
mRNA | Imatinib | FIMM | pan-cancer | AAC | -0.078 | 0.7 |